PHVS

NASDAQ · Pharmaceuticals

Pharvaris Nv

Mid-Cap Stocks Pharmaceutical Stocks Healthcare Stocks

$36.37

-1.63 (-4.29%)

As of Sep 20, 10:09 PM ET ·

PHVS News1 articles

Pharvaris Surges 17% as Phase 3 HAE Trial Meets Primary Endpoint

Pharvaris (PHVS) soared 17% after its oral HAE preventive met the primary endpoint in Phase 3, reducing monthly attacks by 83% versus placebo.